The GLP-1 receptor agonist semaglutide helps 6- to 11-year-old children with obesity reduce their BMI, according to results of the STEP Young trial presented at ObesityWeek, the Obesity Society’s annual meeting.
Percent change in BMI from baseline to week 68, the primary endpoint, was -13.5% with semaglutide and +2.7 with placebo, an estimated between-group difference of -16.2 percentage points (P <0.001). The difference was sustained through 104 weeks.
Semaglutide also improved cardiometabolic measures, including systolic blood pressure, triglycerides, and high-sensitivity C-reactive protein, and, among children with prediabetes, led to a higher rate of reversion to normoglycemia by week 68 (93% vs 56%), reported Ania Jastreboff, MD, PhD, director of the Yale Obesity Research Center in New Haven, CT.
The findings were published simultaneously in the New England Journal of Medicine.
No obesity medications have been FDA-approved for use in children younger than 12, for whom lifestyle modification remains the primary method for weight management despite suboptimal results.
Conflicting guidance on use of obesity drugs in the pediatric population reflects the absence of definitive evidence in children younger than 12, a gap filled by the phase 3 STEP Young trial conducted at 48 sites in nine countries. Overall, 167 children ages 6 to 11 with obesity were randomized 2:1 to once-weekly subcutaneous semaglutide or placebo for 104 weeks, with all participants receiving lifestyle counseling. Mean participant age was 10, and 41% were female. Mean BMI at baseline was 32.5 kg/m2 and mean body weight was 158.5 pounds. About half had at least one obesity-related complication.
In addition to having a greater reduction in BMI, children treated with semaglutide versus placebo were more likely to move into a lower BMI category by week 68 (79% vs 23%) and week 104 (77% vs 24%). BMI fell below the obesity threshold in a greater proportion of children treated with semaglutide at week 68 (38% vs 2%) and week 104 (33% vs 2%).
BMI started to rise after children stopped taking semaglutide at 104 weeks, Dr. Jastreboff noted.
In a subset of participants who underwent DXA scans, semaglutide reduced the proportion of body mass composed of fat and increased the proportion composed of lean soft tissue, which is “very reassuring,” Dr. Jastreboff said.
Presenting the safety results, Antje Körner, MD, PhD, professor of metabolic research at the University of Leipzig in Germany, said semaglutide had no effects on bone mineral density or normal pubertal progression. Children receiving placebo grew slightly taller than those receiving semaglutide, but it could be that GLP-1 receptor agonism is normalizing the accelerated growth seen with obesity, Dr. Körner suggested.
The most common adverse events in the semaglutide group were gastrointestinal (GI), including vomiting, diarrhea, nausea, and abdominal pain, and were mostly mild to moderate in intensity. GI events led to discontinuation in only one semaglutide-treated child.
“Overall, we can reassuringly conclude that there are actually no new safety concerns,” Dr. Körner said.
Discussing the results at ObesityWeek, Daniel Hsia, MD, a pediatric endocrinologist at Emory University in Atlanta, GA, pointed to remaining avenues for research but said STEP Young “supports a paradigm shift, moving away from watchful waiting to earlier treatment of obesity with all available therapies to prevent complications of obesity.”



